TNF Blockers Tied to Hospitalization for Zoster

DR. FURST

The opinions above are excerpted from an editorial accompanying the research report (Ann. Rheum. Dis. 2010;69:1735-7). KEVIN L. WINTHROP, M.D., is in the department of infectious diseases at the Oregon Health and Science University, Portland. DANIEL E. FURST, M.D., is Carl M. Pearson Professor of Rheumatology at the University of California, Los Angeles. Dr. Winthrop reported receiving funding from the Agency for Healthcare Research and Quality for work on the manuscript, and receiving a grant from UCB Pharmaceuticals, as well as consulting fees from Amgen, Wyeth, and Genentech. Dr. Furst reported receiving research support for studies of abatacept, adalimumab, certolizumab, etanercept, infliximab, rituximab, and tocilizumab, and consulting with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genentech, and UCB.